Eli Lilly and Company LLY NYSE

Eli Lilly and Company (LLY) generated $16.81B in operating cash flow for fiscal year 2025. After capital expenditures of $7.84B, free cash flow was $8.97B.

Free cash flow margin was 13.8% of revenue. Cash conversion ratio was 0.81x, suggesting some earnings are non-cash.

The company returned $5.38B in dividends and $4.11B in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (100/100, Pass) — $8.97B (13.8% FCF margin) supports a durable competitive advantage
• INCOME (100/100) — Cash conversion ratio was 0.81x suggests some earnings are non-cash items

Overall SharesGrow Score: 86/100 with 5/7 criteria passed.